Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.

Meanwhile, the Danish drugmaker was also bolstered by the decision by pharmacy benefit manager (PBM) CVS Health to remove Zepbound but retain Wegovy on its formulary of reimbursed medicines.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Zepbound is a prescription drug used for weight loss and weight management in adults. Learn about the drug's dosage, form, strengths, how to use, and more.

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.